Gilead Sciences (GILD) is currently showing above average volatility with an IV Percentile of 95% and an IV Rank of 70.73%.

BioVaxys Technology Corp. (OTC:BVAXF) issued a comprehensive corporate update, detailing its strategic initiatives. BioVaxys ...

The FDA is expected to decide on treatments for multiple myeloma, NSCLC, melanoma, phenylketonuria, and 2 rare kidney diseases.

The interim data, with a cutoff date of April 11, 2025, showed an impressive 70% CR rate. Prior to NXC-201 treatment, the ...

Since its launch in May 2023, Calderys has been participating in HEATERNAL, an EU-funded project working to develop a viable ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest data from a Phase ...

Use of the investigational non-opioid analgesic resiniferatoxin appeared to improve pain control in patients with advanced ...

Panelists discuss how belumosudil is particularly effective for patients with lung involvement due to its antifibrotic mechanism.

At a pre-planned analysis, zilovertamab vedotin 1.75 mg/kg in combination with R-GemOx achieved a 56.3% objective response rate (ORR) in patients with relapsed or refractory DLBCL (n=16), with ...

Merck & Co. has posted phase 2 data on zilovertamab vedotin in lymphoma, providing more evidence of the narrow safety and ...

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall ...

A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing ...